Background: Hepatocarcinogenesis is a complex process that involves various modifications to a number of molecular pathways. Results: The P2Y 2 receptor (P2Y 2 R) mediates the effect of ATP on the cellular behavior of hepatocellular carcinoma (HCC) cells through store-operated calcium channel (SOCs)-mediated Ca 2ϩ signaling. Conclusion: P2Y 2 R is involved in the development and progression of HCC. Significance: P2Y 2 R may be a promising therapeutic target against human HCC.
ATP is an abundant biochemical component of the tumor microenvironment and a physiologic ligand for the P2Y 2 nucleotide receptor (P2Y 2 R). In this study, we investigated the effect of ATP on the cellular behavior of human hepatocellular carcinoma (HCC) cells and the role of P2Y 2 R in ATP action and aimed to find a new therapeutic target against HCC. The experiments were performed in native isolated human HCC cells, normal hepatocytes, human HCC cell lines, and nude mice. We found that the mRNA and protein expression levels of P2Y 2 R in native human HCC cells and the human HCC cell lines HepG2 and BEL-7404 were enhanced markedly compared with human normal hepatocytes and the normal hepatocyte line LO2, respectively. ATP induced intracellular Ca 2؉ increases in HCC cells and promoted the proliferation and migration of HCC cells and the growth of HCC in nude mice. The P2Y receptor antagonist suramin, P2Y 2 R-specific shRNA, the store-operated calcium channel inhibitors 2-aminoethoxydiphenyl borate (2-APB) and 1-(␤-3-(4-methoxy-phenyl) propoxyl-4-methoxyphenethyl)1H-imidazolehydrochloride (SKF96365), and stromal interaction molecule (STIM1)-specific shRNA inhibited the action of ATP on HCC cells. In conclusion, P2Y 2 R mediated the action of ATP on the cellular behavior of HCC cells through store-operated calcium channel-mediated Ca 2؉ signaling, and targeting P2Y 2 R may be a promising therapeutic strategy against human HCC.
Hepatocellular carcinoma (HCC)
4 is a frequent malignant tumor worldwide, and its very poor prognosis makes it the third leading cause of cancer-related mortality. Recent studies demonstrated that the incidence of HCC has increased in the West and in Asia, and it is possible that HCC will be a growing health problem and burden in coming years (1) . Surgical intervention is the most common treatment of HCC, but most patients are ineligible for surgery because of either advanced disease and distant metastases or underlying liver dysfunction (2) . In addition, because the molecular pathogenesis in the promotion and progression of HCC is not clear, the mechanism-based therapies for HCC are rare, and HCC is refractory to nearly all currently available anticancer therapies. Therefore, HCC remains one of the deadliest human cancers, with less than a 5-year survival rate (3) . Therefore, it is of critical importance to look for new therapeutic targets for this disease.
Purinergic receptors comprise a family of transmembrane receptors that are activated by extracellular nucleosides and nucleotides. This large family of receptors has been subdivided into two major classes, P1 and P2. They are distributed widely across animal species, are present ubiquitously on both excitable and nonexcitable mammalian cells, and serve a variety of biological functions, from acting as neurotransmitters to autacoid and paracrine signaling to mitogenesis, angiogenesis, chemotaxis, proliferation and migration of cells, and inflammation (4, 5) . In recent years, most studies have concentrated on the effect of purinergic signaling on the development and progress of tumors. It has been shown that the expression of P2Y receptors is up-regulated in some cancer tissues (6, 7) . Extracellular nucleotides regulate the proliferation of several cancer cell lines through P2Y receptors (8, 9) . In addition to P2Y receptors, P2X and P1 receptors are also involved in tumor growth (10) . These studies indicate that purinergic signaling might be a crucial player in the promotion and progression of tumors, which might open promising perspectives for the development of innovative therapies against tumors.
The P2Y 2 nucleotide receptor (P2Y 2 R) is a member of the purinergic receptor family, belongs to the superfamily of G protein-coupled receptors, and mediates a variety of physiological and pathological responses through multiple and divergent intracellular signaling pathways (4, 11) . P2Y 2 R is expressed in hepatocytes of various species, including humans, and mediates ATP-stimulated intracellular Ca 2ϩ ([Ca 2ϩ ] i ) increases in hepatocytes (12, 13) . However, the role of P2Y 2 R in the promotion and progression of HCC is understood poorly. Therefore, in this study, we investigated the expression and functional role of P2Y 2 R in human HCC and aimed to find a new therapeutic target against HCC.
EXPERIMENTAL PROCEDURES
Reagents-Antibodies directed against P2Y 2 R, P2Y 4 R, proliferating cell nuclear antigen (PCNA), stromal interaction molecule 1 (STIM1), and ␤-actin were purchased from Santa Cruz Biotechnology. Fura-2 acetoxymethylester (Fura-2/AM) was purchased from Invitrogen. ATP, UTP, ADP, suramin, 2-aminoethoxydiphenyl borate (2-APB), 1-(␤-3-(4-methoxy-phenyl)propoxyl-4-methoxyphenethyl)1H-imidazole-hydrochloride (SKF96365), and other routine chemicals were obtained from Sigma, except for those mentioned in the text.
Human Tissue Samples-Human HCC tissues were obtained from eight male patients, aged 40 -50 years, with moderately differentiated primary HCC who underwent surgical resection in the Affiliated Hospital of Zunyi Medical College. The diagnosis of HCC was further confirmed by the histology of resected specimens. Histologically confirmed normal liver tissues were obtained from eight age-matched male patients who underwent surgery for hepatic hemangioma. The tissue samples were collected immediately after surgical resection for cell isolations. This study was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and the guidelines of the Ethics Committee of Zunyi Medical College and were approved by the Ethics Committee of Zunyi Medical College. An informed consent form was signed by each patient.
Isolations of Cancerous Cells of Human HCC Tissues and Hepatocytes of Human Normal Liver
Tissues-Isolation of cancerous cells of native human HCC tissue and hepatocytes of native human normal liver tissues was performed as described previously (14) . Briefly, freshly excised native human HCC tissues were cut into small fragments and incubated in RPMI 1640 medium containing 10 mg/ml collagenase and DNase (4 ml/g of tumor tissue) for 4 h. The single cell suspensions were prepared by pressing the digested tissues through a stainless 200-gauge mesh. After hypotonic lysis of red blood cells, the cells were further isolated by Percoll gradient centrifugation. For the isolation of normal hepatocytes, freshly excised human normal liver tissues were perfused with perfusion solution (Hanks' balanced salt solution, Invitrogen) containing 0.5 mM EGTA and 50 mM HEPES), followed by Williams' medium E (Invitrogen) containing collagenase type IV (0.05%) and 5 mM CaCl 2 . After enzymatic dissociation, the hepatocytes were further separated from nonparenchymal cells through Percoll gradient centrifugation. Then, one portion of the isolated purified cancerous cells or normal hepatocytes was cultured in RPMI 1640 medium plus 10% fetal calf serum for 24 h and was then used for the measurement of [Ca 2ϩ ] i , and another was used for the examination of mRNA and protein expression levels of P2Y 2 R and P2Y 4 R.
Cell Lines and Cell Culture-The human HCC cell lines HepG2 and BEL-7404 and the human normal hepatocyte cell line LO2 were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). All cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum and maintained in an incubator at 37°C and 5%CO 2 .
RNA Extraction and Real-time RT-PCR-Total RNA from HepG2 cells, BEL-7404 cells, and LO2 cells, freshly isolated native human HCC cells, and normal hepatocytes was extracted using RNAiso Plus reagent (Takara Bio, Dalian, China) according to the instructions of the manufacturer. The concentration of all RNA samples was determined spectrophotometrically. The cDNA was produced from 2 g of total RNA using a PrimeScript RT reagent kit (Takara Bio) according to the instructions of the manufacturer. Quantitative real-time RT-PCR was performed on a Bio-Rad iQ5 real-time PCR detection system (Bio-Rad) using a SYBR Premix Ex Taq TM II kit (Takara Bio) following the instructions of the manufacturer. All samples were run in triplicate, and ␤-actin was used as an internal control. The expression level of P2Y 2 R mRNA or P2Y 4 R mRNA was normalized to that of ␤-actin and was expressed as a ratio relative to ␤-actin. The primers were as follows: P2Y 2 R, CTGAG-CATCCTGACCTGGAGA (forward) and CCAGGGCTTTC-ATTGCCATC (reverse); P2Y 4 R, TGCCTGTGAGCTATGC-AGTTGTC (forward) and GGAACATGTAGGTGGCCGTTG (reverse); and ␤-actin, GGAAGGAAGGCTGGAAGAG (forward) and CCTTCCTTCCGACCTTCTC (reverse).
Western Blot Analysis-HepG2 cells, BEL-7404 cells, LO2 cells, freshly isolated native human HCC cells, and normal hepatocytes were homogenized in lysis buffer at 4°C as described previously (14) . The protein concentration of the supernatant was measured by BCA protein assay (Pierce). An equivalent amount of protein from each lysate was subjected to SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. Blots were blocked with 5% nonfat milk and incubated with anti-P2Y 2 R, anti-P2Y 4 R, anti-PCNA, anti-STIM1, or anti-␤-actin (which served as internal control) as the primary antibody. The membranes were washed and incubated with secondary antibody. After additional washing, the blots were developed with enhanced chemiluminescence reagents (Amersham Biosciences Life Science) and exposed to films in a dark room. Protein bands were analyzed with image analysis ] i concentration was quantified from the ratio of 340/380 fluorescence intensities using a method described previously (15) . In each experiment, the [Ca 2ϩ ] i concentration of 10 cells was measured and averaged.
Cell Proliferation Assay-Cell proliferation was measured using both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and BrdU assays. HepG2 or BEL-7404 cells with specific shRNA, non-targeting shRNA, or without shRNA were seeded onto a 24-well plate at a density of 1 ϫ 10 4 cells/well. During the MTT assay, the cells were incubated in ATP, inhibitor plus ATP, or control for 0, 24, 48, or 72 h and then with MTT (0.5 mg/ml) for 4 h at 37°C. The plates were then read at 570 nm using a microplate spectrophotometer. In the BrdU assay, the cells were incubated in ATP, inhibitor plus ATP, or control for 72 h. Cell proliferation was then estimated using a BrdU kit (Roche Diagnostics) following the protocol of the manufacturer. Each experiment was performed in triplicate. The results of the cell proliferation assays were expressed as percent of control. Cell Migration Assay-Cell migration was estimated by using both scratch wound and Transwell migration assays. For the scratch wound migration assay, HepG2 or BEL-7404 cells with specific shRNA, non-targeting shRNA, or without shRNA were cultured on a 24-well plate. The cells were treated with ATP, inhibitor plus ATP, or control. The cell monolayer was then Statistical Analysis-Statistical analysis was processed using the SPSS PC statistics package. All results are expressed as means Ϯ S.E. Data were analyzed by one-way analysis of variance followed by Newman-Keul's post hoc test or, when appropriate, by two-tailed Student's t test. p Ͻ 0.05 was considered to be statistically significant. 4 R in Human HCC Cells-There are at least eight accepted human subtypes of P2Y receptors in which P2Y 2 R and P2Y 4 R are the major subtypes. It has been shown that both P2Y 2 R and P2Y 4 R are expressed in human hepatocytes (12) . Therefore, we first examined the mRNA and protein expression of P2Y 2 R and P2Y 4 R in native human HCC cells and normal hepatocytes. As shown in Fig. 1 , both P2Y 2 R and P2Y 4 R were detected in native human HCC cells and normal hepatocytes, but the mRNA and protein expression levels of P2Y 2 R in native human HCC cells were markedly higher than those in normal hepatocytes (Fig. 1, A1 and B1) (p Ͻ 0.001), whereas there were no significant differences in the mRNA and protein expression levels of P2Y 4 R between native human HCC cells and normal hepatocytes (Fig. 1, A3 were markedly higher than those in normal hepatocytes (Fig. 2,  F1 ) (p Ͻ 0.01), and, likewise, ATP-and UTP-induced [Ca 2ϩ ] i increases in HepG2 cells and BEL-7404 cells were also markedly higher than those in LO2 cells (Fig. 2, F2 ) (p Ͻ 0.05). Suramin, a P2Y receptor antagonist, inhibited ATP-induced [Ca 2ϩ ] i increases in native human HCC cells, HepG2 cells, and BEL-7404 cells (Fig. 3, A1-C3 (Fig. 7, B1-B4 and C1-C4) (p Ͻ 0.0001) and inhibited ATP-induced Ca 2ϩ influxes after the restoration of extracellular Ca 2ϩ in extracellular Ca 2ϩ -free medium (Fig. 7 , D1-D4 and E1-E4) (p Ͻ 0.0001). These results indicate that SOCs are involved in ATP-induced extracellular Ca 2ϩ influx in HCC cells.
RESULTS

Expression of P2Y 2 R and P2Y
P2Y 2 R Mediates ATP-induced Proliferation and Migration of HCC Cells through SOCs-mediated Ca
2ϩ Signaling-We first examined the effects of ATP on the proliferation of HepG2 and BEL-7404 cells by MTT assay. The results showed that ATP promoted the proliferation of both HepG2 cells and BEL-7404 cells time-dependently and that the difference was significant 48 h after administration compared with controls (p Ͻ 0.05) (Fig. 8, A1 and A2) . To further confirm this, BrdU incorporation assay was performed, and the results also showed that ATP markedly promoted the proliferation of both HepG2 cells and BEL-7404 cells (p Ͻ 0.01) (Fig. 8B) . ATP also markedly increased the expression of PCNA protein, a cell proliferation marker, in these cells (p Ͻ 0.01) (Fig. 8, C1 and C2) . The P2Y receptor antagonist suramin and P2Y 2 R-specific shRNA, but not non-targeting shRNA, significantly inhibited ATP-induced HepG2 and BEL-7404 cell proliferation (p Ͻ 0.05 and p Ͻ 0.01, respectively), and suramin had no significant effect on cell proliferation by itself (Fig. 9, A1 and A2) . The SOC inhibitors 2-APB and SKF96365 and STIM1-specific shRNA, but not nontargeting shRNA, also significantly inhibited ATP-induced HepG2 and BEL-7404 cell proliferation (p Ͻ 0.05 and p Ͻ 0.01, respectively), and 2-APB or SKF96365 had no significant effect on cell proliferation by itself (Fig. 9, B1 and B2) .
We further examined the effects of ATP on the migration of HepG2 and BEL-7404 cells. The results from scratch wound and Transwell migration assays showed that ATP promoted the migration of HepG2 cells and BEL-7404 cells. The P2Y receptor antagonist suramin, the SOC inhibitors 2-APB and SKF96365, P2Y 2 R-specific shRNA, and STIM1-specific shRNA, but not non-targeting shRNA, significantly inhibited ATP-induced HepG2 and BEL-7404 cell migration ( Fig. 10 and Fig. 11 ) (p Ͻ 0.001 and p Ͻ 0.0001, respectively). Likewise, suramin, 2-APB, or SKF96365 had no significant effect on cell migration by itself (data not shown). Taken together, these results indicate that P2Y 2 R mediates ATP-induced HCC cell proliferation and migration through SOC-mediated Ca 2ϩ signaling.
P2Y 2 R Mediates ATP-induced Growth of Human HCC through SOC-mediated Ca
2ϩ Signaling-We further studied the effect of ATP on human HCC growth and the role of P2Y 2 R. Heterotopic human HCC implantation in nude mice was performed, and the size of the implanted HCC was observed 10, 15, 20, 25, and 30 days after implantation. As shown in Fig. 12A , ATP markedly promoted the growth of human HCC in nude mice compared with controls (p Ͻ 0.05 and p Ͻ 0.01, respectively). The P2Y receptor antagonist suramin and the SOC inhibitor SKF-96365 markedly inhibited ATP-induced HCC growth in nude mice (p Ͻ 0.05 and p Ͻ 0.01, respectively). Further results showed that P2Y 2 R-and STIM1-specific shRNA, but not non-targeting shRNA, also markedly inhibited ATP-induced HCC growth in nude mice (p Ͻ 0.05 and p Ͻ 0.01, respectively). ATP increased the expression of PCNA protein in the implanted tumor tissue (p Ͻ 0.05), and P2Y 2 R-and STIM1-specific shRNA inhibited an ATP-induced PCNA expression increase (Fig. 12C) . These results indicate that ATP promotes the growth of human HCC through P2Y 2 R-and SOC-mediated Ca 2ϩ signaling.
DISCUSSION
In this study, we found that both P2Y 2 R and P2Y 4 R were expressed in native human HCC cells and normal hepatocytes, the human HCC cell lines HepG2 and BEL-7404, and the human normal hepatocyte line LO2 but that the expression levels of P2Y 2 R rather than P2Y 4 R in native human HCC cells and HCC cell lines were elevated markedly compared with human normal hepatocytes and a normal hepatocyte line, respectively.
Both P2Y 2 R and P2Y 4 R mediate the activation of phospholipase C␤, leading to the production of inositol 1,4,5-trisphosphate and Ca 2ϩ release from the intracellular stores. Nucleotides are ligands for P2Y 2 R and P2Y 4 R. Previous studies have demonstrated that both ATP and UTP have an equivalent potency for P2Y 2 R, whereas ADP is a much less effective agonist for P2Y 2 R and P2Y 4 R and UPT has a higher potency for P2Y 4 R than ATP (4) ] i increase. To determine the role of P2Y 2 R in the promotion and progression of human HCC, we further studied the effects of ATP on the proliferation and migration of HCC cells and HCC growth and the role of P2Y 2 R in ATP action. We found that ATP promoted the proliferation and migration of human HCC cells, both HepG2 and BEL-7404, and the growth of implanted human HCC in nude mice. The P2Y receptor antagonist suramin and P2Y 2 R-specific shRNA inhibited ATP-induced human HCC cell proliferation and migration and the growth of implanted human HCC in nude mice. These results demonstrate that P2Y 2 R mediates the action of ATP on HCC cells. Extracellular nucleotides have emerged as regulators of tumor proliferation and possible effectors of neoplastic transformation. Although other nucleotides, such as UTP and UDP, have important extracellular signaling roles, the most recent studies have highlighted the involvement of ATP in host-tumor interaction. ATP is an abundant biochemical component of the tumor microenvironment and plays an important role in hosttumor interaction (10) . Previous studies found that extracellular ATP concentration was in the 100 mM range in the tumor extracellular milieu, whereas it was undetectable (submicromolar) in healthy tissues (16) . ATP promoted the proliferation of lung cancer cells and breast cancer cells (8, 9) , facilitated the migration of lung cancer cells (17) , and enhanced the invasion of prostate cancer cells (18) . In addition, ATP could rapidly activate multiple components of the c-Jun NH 2 -terminal kinase cascade, a central player in hepatocyte proliferation and liver regeneration (19) . Deletion of Cd39, an ectonucleotidase that regulates extracellular nucleotide/nucleoside concentrations by scavenging nucleotides to ultimately generate adenosine, resulted in higher concentration of extracellular ATP and promoted the development of both induced and spontaneous autochthonous liver cancer in mice (20) . Direct intra-arterial delivery of 3-bromopyruvate, a potent inhibitor of cell ATP production, arrested the growth of liver cancer (21) . These results demonstrate that ATP plays an important role in the development and progression of HCC. In this study, our results demonstrate that the expression of P2Y 2 R is up-regulated in human HCC cells and that P2Y 2 R mediates the action of ATP on the proliferation and migration of human HCC cells and the growth of human HCC. It is well known that inflammation plays an important role in the malignant transformation of tumor cells and the promotion and progression of tumors (22) . Chronic hepatitis induced by hepatitis viruses B and C is a major cause of HCC (23, 24) . In addition, malignant tumors can trigger a strong inflammatory response, and inflammation is a key component of the tumor microenvironment (25) . ATP can be released from inflammatory cells and tumor cells and promotes the development and progression of tumors (10) . Therefore, it is likely that P2Y 2 R is a key player in the development and progression of chronic hepatitis-associated HCC.
P2Y 2 R couples to G proteins to lead to Ca 2ϩ release from the intracellular stores. Ca 2ϩ is a ubiquitous cellular signal. The change of intracellular Ca 2ϩ controls various cellular processes relevant to the development and progression of tumors, such as proliferation, apoptosis, motility, gene transcription, and angiogenesis. Ca 2ϩ signaling proteins and organelles have been emerging as additional cellular targets of oncogenes and tumor therapeutic intervention (26) . In this study, our results demonstrate that both extracellular Ca 2ϩ influx and intracellular Ca 2ϩ ] i increases through P2Y 2 R and that an ATP-induced sustained plateau [Ca 2ϩ ] i increase requires Ca 2ϩ influx from the extracellular space. SOCs are nearly ubiquitous Ca 2ϩ entry pathways stimulated by numerous cell surface receptors via the reduction of Ca 2ϩ concentration in the intracellular stores (27) . 2-APB and SKF96365 are two commonly used SOC inhibitors (28, 29) . In this study, both 2-APB and SKF96365, and specific STIM1 shRNA, a key regulator of SOCs, inhibited ATP-induced extracellular Ca 2ϩ influx in HCC cells, ATP-induced HCC cell proliferation and migration, and HCC growth, demonstrating that P2Y 2 R mediates the action of ATP through SOC-mediated Ca 2ϩ signaling. In summary, hepatocarcinogenesis is a complex process that involves various modifications to a number of molecular pathways as well as genetic alterations and, ultimately, leads to malignant transformation and HCC disease progression (30) . A number of studies have demonstrated a key role of the inflammatory tumor microenvironment in cancer development, progression, and metastasis (22, 31) . ATP can be released from inflammatory cells and tumor cells and accumulates within the tumor microenvironment (10, 16) . In this study, we demonstrate, for the first time, that P2Y 2 R mediates ATP-induced human HCC cell proliferation and migration and HCC growth through SOC-mediated Ca 2ϩ signaling. This means that P2Y 2 R might be a key player in the development and progression of inflammation-associated HCC and that targeting P2Y 2 R is a promising therapeutic strategy against human HCC.
